Discovering therapeutic antibodies designed by nature


PNAS publication: characterization of group 2 Influenza antibodies

December 11, 2013 - A common solution to group 2 influenza virus neutralization

Nature SciBX reviews D25 guided RSV vaccine study

November 14, 2013 - Science-Business eXchange published an article discussing the recent Science study that used AIMMs D25 anti RSV antibody for vaccine design.

Pre-fusion RSV Antibodies

November 4, 2013 - November 4 – AIMM Therapeutics announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved vaccine against RSV.

PLOS pathogens paper

October 11, 2013 - Infection of host tissues by Staphylococcus aureus and S. epidermidis requires an unusual family of staphylococcal adhesive proteins that contain long stretches of serine-aspartate dipeptide-repeats (SDR).

Innovation Credit

September 16, 2013 - AIMM Therapeutics acquired an Innovation Credit of € 2,9 million from the Dutch government for one of our R&D projects.

ERC Advanced Grant

August 13, 2013 - AIMMs CSO Hergen Spits received a prestigious ERC Advanced Grant from the European Research Council.

Nature webcast

July 30, 2013 - AIMM wil present a Nature webcast on July 31.

Scientific advisory board strengthened with new high profile appointments

June 21, 2013 - Bob Löwenberg (Erasmus MC), John Mendelsohn (MD Anderson), and Hidde Ploegh (Whitehead Institute) to join AIMM Scientific advisory board.

Structure of AIMM’s lead antibody D25 binding revealed

April 25, 2013 - Today Science published the pre-fusion cristal of RSV in complex with AIMMs antibody D25.